
-
Ventyx Biosciences NASDAQ:VTYX Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Location: 662 Encinitas Boulevard, Suite 250, CA, 92024, US | Website: ventyxbio.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-121.2M
Cash
217.3M
Avg Qtr Burn
-32.72M
Short % of Float
13.04%
Insider Ownership
4.46%
Institutional Own.
80.52%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTX2735 (NLRP3 inhibitor) Details Recurrent Pericarditis | Phase 2 Data readout | |
VTX3232 Details Obesity and cardiometabolic risk factors | Phase 2 Data readout | |
Tamuzimod (VTX002) (S1P1R modulator) Details Ulcerative colitis | Phase 2 Update | |
VTX958 (TYK2 inhibitor) Details Crohns disease | Phase 2 Update | |
Phase 2a Data readout | ||
VTX958 (TYK2 inhibitor) Details Psoriatic arthritis, Psoriasis | Failed Discontinued |